Verséa Health Inc. Launches New Ocular Surface Disease Quantitative Point-of-Care Test
To aid in the diagnosis and management of ocular surface disease, Verséa Health Inc. has released a new quantitative point-of-care test on the company’s Tear-based Point-of-Care (T-POC) Quantitative Testing Platform.
Verséa shares that Immunoglobulin E (IgE) is a key biomarker associated with allergic conjunctivitis, which has symptoms that can mimic the symptoms of dry eye disease (DED) or infectious conjunctivitis. According to the company, the T-POC Total IgE Immunoassay measures the levels of IgE to provide a numerical value that informs the prescribing decision, allowing eyecare professionals to differentially diagnose a patient’s condition or confirm a desired therapeutic response.
Following this first phase involving the initial shipment of the T-POC Total IgE Immunoassay, Verséa will move onto phase two with the shipment of T-POC Lactoferrin, a test for aqueous deficient DED also for Verséa’s digital reader platform.
Bruder Healthcare Releases Single-Use Soothing Moist Heat Eye Masks
Bruder Healthcare has introduced Eyedration, a single-use eye mask that provides moist heat for treating dry eyes, to address clogged glands in eyelids.
Available in packs of 10, the masks do not require a microwave for heating, Bruder shares, as they begin heating once opened and exposed to air. According to the company, the masks offer eyecare professionals a single-use product that can benefit patients who require manual expression and debridement of the eyelids by warming the lids to encourage a more successful expression of oils before the procedure.